Research To Practice | Oncology Videos

Latest Episodes:

EGFR-Mutated Non-Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting Jul 22, 2026

Show notes

Featuring perspectives from Dr Sarah B Goldberg, Dr Jonathan Goldman, Dr Joel W Neal, Dr Antonio Passaro and Dr Jacob Sands, moderated by Dr Sands, including the following topics:

Introduction (00:00)
Evolving First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Prof Passaro (2:27)
EGFR-Targeted Therapeutic Strategies for Relapsed EGFR-Mutant NSCLC — Dr Neal (36:08)
Utility of TROP2-Targeted Antibody-Drug Conjugates in the Management of EGFR-Mutant NSCLC — Dr Sands (56:16)
Emerging Role of Bispecific Antibody-Based Approaches for EGFR-Mutated NSCLC — Dr Goldman (1:19:08)
Tolerability Considerations with the Use of Available and Emerging Therapies for EGFR-Mutated NSCLC — Dr Goldberg (1:38:46)

CME information and select publications

Endometrial Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting Jul 20, 2026

Show notes

Featuring perspectives from Dr Floor J Backes, Dr Brian M Slomovitz and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:

Introduction (00:00)
Current Up-Front Chemoimmunotherapeutic Approaches for Advanced Endometrial Cancer (EC) — Dr Backes (1:50)
Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy for Advanced EC — Dr Westin (33:15)
Promising Agents Under Investigation for EC — Dr Slomovitz (1:01:41)

CME information and select publications

HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy Jul 18, 2026

Show notes

Featuring an interview with Prof Dr Sibylle Loibl, including the following topics:

Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00)
Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or without pertuzumab (5:35)
Role of endocrine therapy in the treatment of hormone receptor-positive, HER2-positive mBC (8:01)
Targeting the PI3K signaling pathway in HER2-positive mBC (11:08)
Contraindications for T-DXd; T-DXd-associated gastrointestinal toxicities and interstitial lung disease (13:53)
Optimal duration of and therapeutic partner for T-DXd as first-line maintenance therapy for patients with HER2-positive mBC (20:44)
Case: A woman in her early 40s with metastatic relapse of HER2-positive breast cancer 2 years after completing neoadjuvant and adjuvant therapy (26:54)
Role of exercise and weight control in the management of breast cancer; effect of pregnancy on the breast tumor immune environment (40:03)

CME information and select publications

HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy (Companion Faculty Lecture) Jul 17, 2026

Show notes

Featuring a slide presentation and related discussion from Prof Dr Sibylle Loibl, including the following topics:

· Overview of the changing landscape of treatment for patients with HER2-positive metastatic breast cancer (mBC) (0:00)

· Results from the CLEOPATRA, PATINA and HER2CLIMB-05 trials of first-line treatment and maintenance approaches for HER2-positive mBC (5:26)

· Efficacy and safety findings from the Phase III DESTINY-Breast09 trial comparing trastuzumab deruxtecan with or without pertuzumab to taxane/trastuzumab/pertuzumab as first-line therapy for HER2-positive mBC (14:56)

· Predictors of long-term benefit from first-line treatment with HER2-targeted agents; contribution of pertuzumab to the efficacy of first-line HER2-targeted combination regimens (22:57)

· Control of brain metastases and CNS disease with first-line HER2-targeted regimens (26:31)

CME information and select publications

For Oncology Nurses: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Congress Jul 16, 2026

Show notes

Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics:

Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00)
Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49)
Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48)
Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43)
Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43)
Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15)
Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30)

CME information and select publications

Ovarian Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting Jul 15, 2026

Show notes

Featuring perspectives from Dr Ramez N Eskander, Dr Ursula Matulonis, Dr Kathleen N Moore, Dr Alexander B Olawaiye and Dr David M O'Malley, moderated by Dr Moore, including the following topics:

Introduction (00:00)
Current Role of PARP Inhibitors in the Management of Advanced Ovarian Cancer (OC) — Prof Eskander (2:40)
Strategies Targeting Folate Receptor Alpha in Advanced OC — Dr Matulonis (27:41)
Other Approved and Promising Investigational Antibody-Drug Conjugates for Advanced OC — Dr Moore (52:12)
Other Novel Agents and Strategies for Advanced OC — Dr O'Malley (1:14:35)
Diagnosis and Management of Adverse Events Associated with Common Therapies for Advanced OC — Dr Olawaiye (1:39:39)

CME information and select publications

HER2-Altered Non-Small Cell Lung Cancer — Rapid Case Review Jul 14, 2026

Show notes

Featuring an interview with Dr Mark Jeng and Dr Joshua K Sabari, including the following topics:

· Case: A woman in her late 90s with recurrent HER2-mutant metastatic non-small cell lung cancer (NSCLC) receives third-line zongertinib (0:00)

· Case: A woman in her early 60s with multiregimen-recurrent HER2-mutant metastatic NSCLC experiences a response to zongertinib (8:07)

· Case: A man in his mid 80s experiences metastatic recurrence after resection of PD-L1-positive, HER2-mutant metastatic NSCLC (17:50)

CME information and select publications

Localized HR-Positive Breast Cancer — Year in Review Series on Relevant New Datasets and Advances Jul 13, 2026

Show notes

Featuring perspectives from Dr Harold J Burstein and Dr Joyce O'Shaughnessy, including the following topics:

Introduction: ODAC — April 30, 2026 (00:00)
Adjuvant CDK4/6 Inhibitors (13:03)
Adjuvant Oral Selective Estrogen Receptor Degraders (21:53)
Premenopausal Patients (30:52)
Duration of Adjuvant Endocrine Treatment (38:44)
Genomic Predictors of Chemotherapy Benefit (47:19)
Neoadjuvant Treatment (55:13)

CME information and select publications

Localized HR-Positive Breast Cancer | Joyce O'Shaughnessy, MD Jul 13, 2026

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Localized HR-Positive Breast Cancer | Faculty Presentation 2: Genomic Evaluation for Treatment Decision-Making in Localized HR-Positive Breast Cancer — Joyce O'Shaughnessy, MD

CME information and select publications

Localized HR-Positive Breast Cancer | Harold J Burstein, MD, PhD Jul 13, 2026

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Localized HR-Positive Breast Cancer | Faculty Presentation 1: Advances in the Use of Endocrine Therapy for Localized HR-Positive Breast Cancer — Harold J Burstein, MD, PhD

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected